facebook
twitter
rss
account
search
search
 

Rosy Phase 1 results for ImmunoGen drug

Nov. 16, 2005 at 2:15 PM   |   Comments

CAMBRIDGE, Mass., Nov. 16 (UPI) -- ImmunoGen said Wednesday that its investigational drug dubbed huN901-DM1 shows promise in fighting solid tumors.

The compound appears to cause complete remission in patients with small-cell lung cancer or other CD56-expressing solid tumors, lasting at least 15 weeks, and disease stability lasting up to 18 weeks, the Cambridge, Mass.-based firm said in a statement.

ImmunoGen presented its Phase 1 clinical findings on the tumor-activated prodrug compound at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.

In the ongoing trial, the drug is being administered daily for three consecutive days in a 21-day cycle to patients with CD56-expressing solid tumors, ImmunoGen said.

New cohorts of patients receive progressively higher doses of huN901-DM1 until the maximum tolerated dose is established, the company said.

All study patients have relapsed or refractory small-cell lung cancer (SCLC) or other CD56-expressing solid tumors.

© 2005 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Recommended UPI Stories
Featured UPI Collection
trending
Notable deaths of 2014 [PHOTOS]

Notable deaths of 2014 [PHOTOS]

Most Popular
1
Doctor to Jim Kelly: no evidence of cancer
2
New research explains insomnia prevalence among elderly
3
New data shows Melbourne is most well-rested city in the world
4
New research details rare cancer that killed Bob Marley
5
Daughters more likely than sons to care for elder parents
Trending News
Video
x
Feedback